Raelipskie Partnership’s Novo Nordisk NVO Stock Holding History

Raelipskie Partnership’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$656K	Buy	17,848 +966	+6%	+$45.8K	0.28%	57
2025 Q4	$859K	Sell	16,882 -638	-4%	-$32.6K	0.36%	51
2025 Q3	$972K	Sell	17,520 -805	-4%	-$47.1K	0.42%	48
2025 Q2	$1.26M	Sell	18,325 -300	-2%	-$20.4K	0.58%	44
2025 Q1	$1.29M	Buy	18,625 +3,007	+19%	+$248K	0.66%	39
2024 Q4	$1.34M	Buy	15,618 +3,000	+24%	+$324K	0.67%	38
2024 Q3	$1.5M	Hold	12,618	–	–	0.73%	32
2024 Q2	$1.8M	Buy	+12,618	New	+$1.67M	0.96%	25

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Raelipskie Partnership's NVO Position: Q1 2026 in Review

Raelipskie Partnership increased its Novo Nordisk (NVO) stake by 5.7% in Q1 2026, buying an estimated $45.8K and bringing the position to 17,848 shares worth $656K. The position accounts for 0.28% of the portfolio, ranked #57.

Raelipskie Partnership first reported a position in NVO in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.8M in Q2 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Raelipskie Partnership held 17,848 shares of Novo Nordisk worth $656K as of Q1 2026.
Raelipskie Partnership bought 966 Novo Nordisk shares in Q1 2026, an estimated $45.8K.
Novo Nordisk made up 0.28% of Raelipskie Partnership's portfolio in Q1 2026, its #57 holding.
Raelipskie Partnership first reported a position in Novo Nordisk in Q2 2024 and has held it in 8 quarters since.
Raelipskie Partnership's Novo Nordisk position peaked at $1.8M in Q2 2024.
1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Raelipskie Partnership's 13F filing for Q1 2026, filed 29 Apr 2026.